What is claimed is:

1. An anti-PD-L1 antibody, the antibody comprising a heavy chain having an amino acid sequence of SEQ ID NO: 85 and a light chain having an amino acid sequence of SEQ ID NO: 87.

2. A nucleic acid molecule, comprising a nucleic acid sequence capable of encoding a polypeptide having a sequence selected from the group consisting of:

SEQ ID NO: 85; and SEQ ID NO: 87.

3. The nucleic acid molecule of claim 2, said nucleic acid molecule comprising a sequence of SEQ ID NO: 86 or SEQ ID NO: 88.

4. A host cell, comprising a nucleic acid capable of encoding a polypeptide having a sequence selected from the group consisting of:

SEQ ID NO: 85; and SEQ ID NO: 87.

5. A composition, comprising:

an antibody having a heavy chain of SEQ ID NO: 85 and a light chain of SEQ ID NO: 87, or an antigen binding portion of the antibody; and

a pharmaceutically acceptable excipient or adjuvant.

6. The composition of claim 5, comprising about 275 mM serine, about 10 mM histidine, having pH of about 5.9.

7. The composition of claim 5, comprising about 0.05% polysorbate 80, about 1% D-mannitol, about 120 mM L-proline,

about 100 mM L-serine, about 10 mM L-histidine-HCl, having pH of about 5.8.

8. Use of a pharmaceutical composition comprising an antibody having a heavy chain of SEQ ID NO. 85 and a light chain of SEQ ID NO. 87, or an antigen binding portion of the antibody in the preparation of a medicament for treating or preventing a disease or condition associated with modulation of activity of human PD-L1.

9. The use of claim 8, wherein said disease is a lung cancer, ovarian cancer, colon cancer, colorectal cancer, melanomas, kidney cancer, bladder cancer, breast cancer, liver cancer, lymphomas, hematologic malignancies, head and neck cancer, gliomas, gastric cancer, nasopharyngeal cancer, laryngeal cancer, cervical cancer, uterine cancer or osteosarcomas.

10. The use of claim 9, wherein said disease is a HBV, HCV or HIV infection.